ANRS, Emerging Infectious Diseases

Quick facts

Marketed products

• Antiretroviral therapy · Infectious Disease / Virology
  Antiretroviral therapy (ART) suppresses HIV replication by blocking viral enzymes (reverse transcriptase, integrase, protease) and/or preventing viral entry into CD4+ T cells.
• blood sampling · Diagnostics / Infectious Disease Surveillance
  Blood sampling is a diagnostic procedure that collects blood specimens for laboratory analysis to detect pathogens, assess immune response, or monitor disease markers.
• Ervebo · Other
• Fumarate, Tenofovir Disoproxil
• Inmazeb · Immunology
• Lamivudine Oral Solution · Infectious Disease
  Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA.
• Pegylated Interferon alpha-2a · Immunology, Virology, Oncology
  Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity.
• Reinforced preventive ARV therapy
• Rifampin, isoniazid, pyrazinamide, ethambutol · Infectious Disease
  This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis.
• Sofosbuvir and Daclatasvir for 24 weeks · Infectious Disease / Virology
  Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA polymerase while daclatasvir inhibits NS5A protein, together blocking viral replication.
• Veklury · Metabolic

Phase 3 pipeline

• ARV bitherapie · Infectious Disease
  ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes.
• atazanavir boosted with ritonavir · Infectious diseases
  Atazanavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing the virus from replicating.
• Bexsero® vaccine · Immunology / Infectious Disease
  Bexsero is a recombinant meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.
• Cabotegravir Tablets, for oral use. · Infectious Disease / Virology
  Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.
• darunavir; ritonavir; emtricitabine/tenofovir · Infectious Disease
  This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
• darunavir/ritonavir QD + raltegravir BID · Infectious Diseases
  Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication.
• Experimental: doxycycline · Infectious Diseases
  Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.
• GenHevac-B · Immunology / Infectious Disease
  GenHevac-B is a therapeutic hepatitis B vaccine designed to boost immune response in chronically infected patients by presenting hepatitis B surface antigen (HBsAg) to stimulate T-cell and B-cell immunity.
• GenHevac B Pasteur · Immunology / Infectious Disease
  GenHevac B Pasteur is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen.
• Intensified TBM treatment · Infectious Diseases
  Intensified TBM treatment uses higher doses and/or more frequent administration of anti-tuberculous drugs to improve penetration into the central nervous system and enhance bacterial killing in tuberculous meningitis.
• Maraviroc (Celsentri) · Infectious Disease
  Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.
• Nucleotidic or Nucleosidic Treatment · Infectious Disease; Virology
  Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens.
• Tenofovir + lamivudine + raltegravir · Infectious Diseases
  Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome.
• Treatment discontinuation · Infectious Diseases
  Treatment discontinuation is a process where a patient stops taking a medication.
• WHO TBM treatment · Infectious Disease
  WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system.

Phase 2 pipeline

• ABC-3TC-EFV once a day
• administration of SLGN in arm C
• Amniotic fluid sampling · Obstetrics
  Amniotic fluid sampling is a diagnostic procedure that involves collecting a sample of amniotic fluid for analysis.
• BBIBP-CorV
• blood drawn
• Boceprevir, Peg-interferon alfa 2b and Ribavirin
• Breast milk sampling · Pediatrics
  This drug is used to monitor the levels of various substances in breast milk.
• darunavir monotherapy
• Fluoxétine and Budésonide · Psychiatry, Respiratory
  Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and budesonide is a corticosteroid.
• GTU-multHIV B vaccine and LIPO-5 vaccine · Infectious Disease
  The GTU-multHIV B vaccine and LIPO-5 vaccine target multiple HIV epitopes to stimulate both humoral and cellular immune responses.
• Methylphenidate Pill
• Nitazoxanide and Ciclésonide
• raltegravir and etravirine
• Structured treatment interruption
• Vaginal swab

Phase 1 pipeline

• A peripheral blood sample
• Combi 0.3 group
• Combi 1 group
• Combi 3 group
• Cormirnaty · Other
• Decitabine cycle 1
• Decitabine cycle 2
• Decitabine cycle 3
• Decitabine cycle 4
• HCV treatment
• HIV prevention package including PrEP
• Late boost CD40 adjuvanted
• Late boost CD40 alone
• LVT-001
• PrEP with Truvada®
• Romidepsin cycle 1
• Romidepsin cycle 2
• Romidepsin cycle 3
• Romidepsin cycle 4
• Solo 0.3 group
• Solo 1 group
• Solo 3 group

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ANRS, Emerging Infectious Diseases portfolio CI brief
• ANRS, Emerging Infectious Diseases pipeline updates RSS